secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001628280-24-006142
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027
--------------------------------------------------------------------------------

- Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.
- Revenue fell to $20.8M from $31.1M, mainly due to end of Calico collaboration.
- Cash, equivalents and marketable securities at Dec 31, 2023: $281.7M; proforma ~$330M with Jan 2024 inflows, funding into 2027.
- Workforce reduced ~30% in Jan 2024; trials for CFT7455 and CFT1946 continue, data expected 2H2024.
- Collaborations: Merck deal up to $2.5B milestone potential; Betta paid $25M, CTA approved in China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/0001628280-24-006142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024006142/cccc-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-006142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer